X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (837) 837
Publication (133) 133
Book Review (12) 12
Book Chapter (5) 5
Government Document (3) 3
Conference Proceeding (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (740) 740
index medicus (506) 506
oncology (410) 410
animals (374) 374
female (301) 301
cell line, tumor (294) 294
receptor, erbb-3 - metabolism (293) 293
receptor, erbb-2 - metabolism (250) 250
receptor, epidermal growth factor - antagonists & inhibitors (235) 235
cancer (224) 224
mice (215) 215
receptor, erbb-3 - antagonists & inhibitors (209) 209
signal transduction (202) 202
receptor, erbb-2 - antagonists & inhibitors (187) 187
receptor, epidermal growth factor - metabolism (185) 185
signal transduction - drug effects (165) 165
growth-factor receptor (156) 156
expression (155) 155
receptor, erbb-3 - genetics (155) 155
antineoplastic agents - pharmacology (153) 153
breast cancer (146) 146
epidermal growth factor (146) 146
egfr (142) 142
phosphorylation (142) 142
research (132) 132
biochemistry & molecular biology (129) 129
cell biology (127) 127
antineoplastic agents - therapeutic use (125) 125
cell proliferation - drug effects (125) 125
receptor, erbb-2 - genetics (121) 121
protein kinase inhibitors - pharmacology (118) 118
quinazolines - pharmacology (118) 118
epidermal-growth-factor (116) 116
breast neoplasms - drug therapy (115) 115
kinases (115) 115
breast neoplasms - metabolism (112) 112
skin and connective tissue diseases (109) 109
male (108) 108
activation (105) 105
receptor, epidermal growth factor - genetics (105) 105
ligands (104) 104
article (103) 103
breast neoplasms - pathology (103) 103
breast-cancer (103) 103
mutation (99) 99
care and treatment (98) 98
proteins (97) 97
trastuzumab (93) 93
tumors (93) 93
tyrosine kinase inhibitor (92) 92
gefitinib (90) 90
xenograft model antitumor assays (90) 90
health aspects (89) 89
proto-oncogene proteins c-akt - metabolism (89) 89
erbb3 (87) 87
tyrosine (86) 86
drug resistance, neoplasm (85) 85
apoptosis (84) 84
gene expression (83) 83
her3 (79) 79
her2 (78) 78
protein kinase inhibitors - therapeutic use (77) 77
research article (77) 77
cell lung-cancer (75) 75
therapy (75) 75
genetic aspects (74) 74
antibodies, monoclonal - pharmacology (73) 73
lung neoplasms - drug therapy (73) 73
tyrosine kinase (73) 73
breast neoplasms - genetics (72) 72
lung-cancer (72) 72
monoclonal-antibody (72) 72
acquired-resistance (71) 71
phosphatidylinositol 3-kinases - metabolism (71) 71
gene expression regulation, neoplastic (69) 69
analysis (68) 68
neoplasms (68) 68
neoplasms - drug therapy (68) 68
antibodies, monoclonal - therapeutic use (67) 67
apoptosis - drug effects (67) 67
mice, nude (67) 67
cell proliferation (66) 66
receptor, erbb-4 (65) 65
medicine & public health (63) 63
resistance (63) 63
cetuximab (62) 62
factor receptor (62) 62
blotting, western (61) 61
carcinoma, non-small-cell lung - drug therapy (60) 60
genetics & heredity (60) 60
pharmacology & pharmacy (59) 59
biology (58) 58
chemotherapy (58) 58
erbb receptors - antagonists & inhibitors (58) 58
receptor (58) 58
egf receptor (57) 57
lung cancer (57) 57
medicine (57) 57
cancer research (56) 56
tyrosine kinase inhibitors (56) 56
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 3/2005, Volume 102, Issue 10, pp. 3788 - 3793
Journal Article
Nature, ISSN 0028-0836, 02/2018, Volume 554, Issue 7691, pp. 189 - 194
Journal Article
Cancer Research, ISSN 0008-5472, 10/2013, Volume 73, Issue 19, pp. 6024 - 6035
HER2/HER3 dimerization resulting from overexpression of HER2 or neuregulin (NRG1) in cancer leads to HER3-mediated oncogenic activation of phosphoinositide... 
BREAST-CANCER | EXTRACELLULAR REGION | COMPLEX | DOMAIN | ACTIVATION | ERBB3 | ONCOLOGY | AFFINITY | CRYSTAL-STRUCTURE | FACTOR RECEPTOR | TRASTUZUMAB RESISTANCE | Receptor, ErbB-3 - metabolism | Immunoprecipitation | Humans | Protein Conformation - drug effects | Receptor, ErbB-2 - metabolism | Immunoblotting | Receptor, ErbB-3 - chemistry | Breast Neoplasms - metabolism | Receptor, Epidermal Growth Factor - metabolism | Receptor, ErbB-3 - immunology | Antibodies, Monoclonal, Humanized - pharmacology | Female | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Phosphorylation - drug effects | Tumor Cells, Cultured | Proto-Oncogene Proteins c-akt - metabolism | Signal Transduction | Receptor, ErbB-3 - antagonists & inhibitors | Survival Rate | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Breast Neoplasms - pathology | Mice, Nude | Neuregulin-1 - metabolism | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Breast Neoplasms - mortality | Mice, Inbred NOD | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Protein Multimerization - drug effects | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | BASIC BIOLOGICAL SCIENCES | 60 APPLIED LIFE SCIENCES | PI-3 kinase | NRG | ligand-independent | Antibody | neuregulin | SCCHN | EGFR | resistance | feedback | HER | PIK3CA | cancer | HER2 | HER3 | ligand-dependent
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 01/2016, Volume 291, Issue 3, pp. 1029 - 1052
N-MYC downstream-regulated gene-1 (NDRG1) is a potent growth and metastasis suppressor that acts through its inhibitory effects on a wide variety of cellular... 
BREAST-CANCER | ISONICOTINOYL HYDRAZONE CLASS | ACTIVATED PROTEIN-KINASE | TGF-BETA | IRON CHELATORS | PHOSPHATIDYLINOSITOL 3-KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | EPIDERMAL-GROWTH-FACTOR | EFFECTIVE ANTIPROLIFERATIVE AGENTS | PANCREATIC-CANCER | SELECTIVE ANTITUMOR-ACTIVITY | Receptor, ErbB-3 - metabolism | Pancreatic Neoplasms - metabolism | Receptor, ErbB-2 - genetics | Humans | Antineoplastic Agents - therapeutic use | Intracellular Signaling Peptides and Proteins - metabolism | Antineoplastic Agents - administration & dosage | Colonic Neoplasms - metabolism | RNA Interference | Receptor, ErbB-2 - antagonists & inhibitors | Intracellular Signaling Peptides and Proteins - genetics | ErbB Receptors - antagonists & inhibitors | Pancreatic Neoplasms - pathology | Cell Cycle Proteins - metabolism | Receptor, ErbB-3 - antagonists & inhibitors | Recombinant Proteins - chemistry | Random Allocation | Receptor, ErbB-3 - agonists | Receptor, ErbB-3 - genetics | Mice, Nude | Cell Line, Tumor | Receptor, ErbB-2 - agonists | Colonic Neoplasms - drug therapy | ErbB Receptors - genetics | Receptor, ErbB-2 - metabolism | Cell Cycle Proteins - antagonists & inhibitors | Pancreatic Neoplasms - drug therapy | Cell Cycle Proteins - genetics | Female | Antineoplastic Agents - pharmacology | Thiosemicarbazones - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Pyridines - therapeutic use | Recombinant Proteins - metabolism | ErbB Receptors - metabolism | Epidermal Growth Factor - genetics | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Epidermal Growth Factor - metabolism | Cell Cycle Proteins - agonists | Xenograft Model Antitumor Assays | Animals | MAP Kinase Signaling System - drug effects | Thiosemicarbazones - therapeutic use | Tumor Burden - drug effects | Colonic Neoplasms - pathology | Intracellular Signaling Peptides and Proteins - agonists | Epidermal Growth Factor - antagonists & inhibitors | Pyridines - pharmacology | ErbB Receptors - agonists | Molecular Bases of Disease | cancer therapy | anticancer drug | pharmaceutics | metastasis suppressor | molecular pharmacology | pharmacology | thiosemicarbazones | tumor cell biology | NDRG1 | Dp44mT
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2009, Volume 15, Issue 17, pp. 5445 - 5456
Purpose: The insulin-like growth factor (IGF) signaling axis is frequently dysregulated in hepatocellular carcinoma (HCC). Therefore, we investigated whether... 
targeted therapy | AVE1642 | gefitinib | HER3/erbB-3 | hepatocellular carcinoma | CANCER-CELLS | HUMAN HEPATOMA | ACTIVATION | ONCOLOGY | TYROSINE KINASE | MYELOMA CELLS | ACQUIRED-RESISTANCE | SENSITIVITY | CELL-LINES | MESENCHYMAL TRANSITION | EXPRESSION | Phosphorylation - physiology | Receptor, ErbB-3 - metabolism | Receptor, IGF Type 1 - antagonists & inhibitors | Antibiotics, Antineoplastic - pharmacology | Humans | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Carcinoma, Hepatocellular - drug therapy | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Cell Survival - physiology | Cell Survival - drug effects | Antibodies, Monoclonal - pharmacology | Liver Neoplasms - drug therapy | Receptor, ErbB-3 - antagonists & inhibitors | Receptor, ErbB-3 - agonists | Sirolimus - pharmacology | Drug Synergism | Insulin - metabolism | Signal Transduction - drug effects | Liver Neoplasms - metabolism | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Signal Transduction - physiology | Quinazolines - pharmacology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Carcinoma, Hepatocellular - metabolism | RNA, Small Interfering - metabolism | Index Medicus
Journal Article
Cell Reports, ISSN 2211-1247, 2014, Volume 7, Issue 1, pp. 86 - 93
Journal Article
Cancer Cell, ISSN 1535-6108, 10/2011, Volume 20, Issue 4, pp. 472 - 486
Extensive crosstalk among ErbB/HER receptors suggests that blocking signaling from more than one family member may be essential to effectively treat cancer and... 
CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | ACTIVATION | GEFITINIB | THERAPY | ERBB3 | ONCOLOGY | ACQUIRED-RESISTANCE | MONOCLONAL-ANTIBODY | METASTATIC COLORECTAL-CANCER | CELL BIOLOGY | Antibody Specificity | Phosphorylation | Humans | Antibodies, Monoclonal - adverse effects | Macaca fascicularis | Antibodies, Monoclonal - therapeutic use | Crystallography, X-Ray | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Receptor, ErbB-3 - chemistry | Antineoplastic Agents - toxicity | MAP Kinase Signaling System | Antibodies, Monoclonal, Humanized | Receptor, ErbB-3 - immunology | Female | Cetuximab | Drug Evaluation, Preclinical | Proto-Oncogene Proteins c-akt - metabolism | Binding, Competitive | Receptor, Epidermal Growth Factor - immunology | Signal Transduction | Immunoglobulin G - chemistry | Immunoglobulin G - therapeutic use | Receptor, ErbB-3 - antagonists & inhibitors | Antineoplastic Agents - chemistry | Receptor, Epidermal Growth Factor - chemistry | Immunoglobulin G - adverse effects | Antibodies, Bispecific - therapeutic use | Animals | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Antibodies, Bispecific - chemistry | Mice | Antibodies, Bispecific - toxicity | Binding Sites, Antibody | Care and treatment | Immunoglobulin G | Comparative analysis | Drug resistance | Saturated fatty acids | Antigenic determinants | Cancer
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 2017, Volume 292, Issue 31, pp. 12772 - 12782
The iron-regulated metastasis suppressor N-myc downstream-regulated gene 1 (NDRG1) has been shown to inhibit numerous oncogenic signaling pathways in cancer... 
ANTIPROLIFERATIVE ACTIVITY | TGF-BETA | epidermal growth factor receptor (EGFR) | BIOCHEMISTRY & MOLECULAR BIOLOGY | PANCREATIC-CANCER | TYROSINE KINASES | NDRG1 | EPITHELIAL-MESENCHYMAL TRANSITION | BREAST-CANCER | cancer therapy | TUMOR-CELL MIGRATION | metastasis | cell signaling | PROSTATE-CANCER |